206 related articles for article (PubMed ID: 30770901)
1. Neurotensin and its receptors mediate neuroendocrine transdifferentiation in prostate cancer.
Zhu S; Tian H; Niu X; Wang J; Li X; Jiang N; Wen S; Chen X; Ren S; Xu C; Chang C; Flores-Morales A; Shang Z; Sun Y; Niu Y
Oncogene; 2019 Jun; 38(24):4875-4884. PubMed ID: 30770901
[TBL] [Abstract][Full Text] [Related]
2. Elevated circulating tissue inhibitor of metalloproteinase 1 (TIMP-1) levels are associated with neuroendocrine differentiation in castration resistant prostate cancer.
Gong Y; Chippada-Venkata UD; Galsky MD; Huang J; Oh WK
Prostate; 2015 May; 75(6):616-27. PubMed ID: 25560638
[TBL] [Abstract][Full Text] [Related]
3. c-MYC drives histone demethylase PHF8 during neuroendocrine differentiation and in castration-resistant prostate cancer.
Maina PK; Shao P; Liu Q; Fazli L; Tyler S; Nasir M; Dong X; Qi HH
Oncotarget; 2016 Nov; 7(46):75585-75602. PubMed ID: 27689328
[TBL] [Abstract][Full Text] [Related]
4. Macrophages induce neuroendocrine differentiation of prostate cancer cells via BMP6-IL6 Loop.
Lee GT; Kwon SJ; Lee JH; Jeon SS; Jang KT; Choi HY; Lee HM; Kim WJ; Lee DH; Kim IY
Prostate; 2011 Oct; 71(14):1525-37. PubMed ID: 21374653
[TBL] [Abstract][Full Text] [Related]
5. Function and mechanism of neurotensin (NTS) and its receptor 1 (NTSR1) in occurrence and development of tumors.
Hu HR; Dong Z; Yi L; He XY; Zhang YL; Liu YL; Cui HJ
Zhongguo Zhong Yao Za Zhi; 2015 Jul; 40(13):2524-36. PubMed ID: 26697673
[TBL] [Abstract][Full Text] [Related]
6. Neuroendocrine Differentiation in Prostate Cancer: Emerging Biology, Models, and Therapies.
Puca L; Vlachostergios PJ; Beltran H
Cold Spring Harb Perspect Med; 2019 Feb; 9(2):. PubMed ID: 29844220
[TBL] [Abstract][Full Text] [Related]
7. Induction of neuroendocrine differentiation in castration resistant prostate cancer cells by adipocyte differentiation-related protein (ADRP) delivered by exosomes.
Lin LC; Gao AC; Lai CH; Hsieh JT; Lin H
Cancer Lett; 2017 Apr; 391():74-82. PubMed ID: 28109910
[TBL] [Abstract][Full Text] [Related]
8. Expression of neuroendocrine differentiation markers in lethal metastatic castration-resistant prostate cancer.
Sainio M; Visakorpi T; Tolonen T; Ilvesaro J; Bova GS
Pathol Res Pract; 2018 Jun; 214(6):848-856. PubMed ID: 29728311
[TBL] [Abstract][Full Text] [Related]
9. MicroRNA determinants of neuroendocrine differentiation in metastatic castration-resistant prostate cancer.
Bhagirath D; Liston M; Patel N; Akoto T; Lui B; Yang TL; To DM; Majid S; Dahiya R; Tabatabai ZL; Saini S
Oncogene; 2020 Dec; 39(49):7209-7223. PubMed ID: 33037409
[TBL] [Abstract][Full Text] [Related]
10. Neuroendocrine differentiation in castration resistant prostate cancer. Nuclear medicine radiopharmaceuticals and imaging techniques: A narrative review.
Usmani S; Orevi M; Stefanelli A; Zaniboni A; Gofrit ON; Bnà C; Illuminati S; Lojacono G; Noventa S; Savelli G
Crit Rev Oncol Hematol; 2019 Jun; 138():29-37. PubMed ID: 31092382
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of neurotensin receptor 1 as potential biomarker for prostate cancer theranostic use.
He T; Wang M; Wang H; Tan H; Tang Y; Smith E; Wu Z; Liao W; Hu S; Li Z
Eur J Nucl Med Mol Imaging; 2019 Sep; 46(10):2199-2207. PubMed ID: 31264168
[TBL] [Abstract][Full Text] [Related]
12. Patient-derived Hormone-naive Prostate Cancer Xenograft Models Reveal Growth Factor Receptor Bound Protein 10 as an Androgen Receptor-repressed Gene Driving the Development of Castration-resistant Prostate Cancer.
Hao J; Ci X; Xue H; Wu R; Dong X; Choi SYC; He H; Wang Y; Zhang F; Qu S; Zhang F; Haegert AM; Gout PW; Zoubeidi A; Collins C; Gleave ME; Lin D; Wang Y
Eur Urol; 2018 Jun; 73(6):949-960. PubMed ID: 29544736
[TBL] [Abstract][Full Text] [Related]
13. Differential expression and tumorigenic function of neurotensin receptor 1 in neuroendocrine tumor cells.
Kim JT; Li J; Song J; Lee EY; Weiss HL; Townsend CM; Evers BM
Oncotarget; 2015 Sep; 6(29):26960-70. PubMed ID: 26298774
[TBL] [Abstract][Full Text] [Related]
14. The Neuropilin-1/PKC axis promotes neuroendocrine differentiation and drug resistance of prostate cancer.
Blanc C; Moktefi A; Jolly A; de la Grange P; Gay D; Nicolaiew N; Semprez F; Maillé P; Soyeux P; Firlej V; Vacherot F; Destouches D; Amiche M; Terry S; de la Taille A; Londoño-Vallejo A; Allory Y; Delbé J; Hamma-Kourbali Y
Br J Cancer; 2023 Mar; 128(5):918-927. PubMed ID: 36550208
[TBL] [Abstract][Full Text] [Related]
15.
Bhagirath D; Yang TL; Tabatabai ZL; Majid S; Dahiya R; Tanaka Y; Saini S
Clin Cancer Res; 2019 Nov; 25(21):6532-6545. PubMed ID: 31371344
[TBL] [Abstract][Full Text] [Related]
16. The role of high cell density in the promotion of neuroendocrine transdifferentiation of prostate cancer cells.
Pernicová Z; Slabáková E; Fedr R; Šimečková Š; Jaroš J; Suchánková T; Bouchal J; Kharaishvili G; Král M; Kozubík A; Souček K
Mol Cancer; 2014 May; 13():113. PubMed ID: 24884804
[TBL] [Abstract][Full Text] [Related]
17. The Internalization of Neurotensin by the Low-Affinity Neurotensin Receptors (NTSR2 and vNTSR2) Activates ERK 1/2 in Glioma Cells and Allows Neurotensin-Polyplex Transfection of tGAS1.
Ayala-Sarmiento AE; Martinez-Fong D; Segovia J
Cell Mol Neurobiol; 2015 Aug; 35(6):785-95. PubMed ID: 25772140
[TBL] [Abstract][Full Text] [Related]
18. HOTAIR is a REST-regulated lncRNA that promotes neuroendocrine differentiation in castration resistant prostate cancer.
Chang YT; Lin TP; Tang JT; Campbell M; Luo YL; Lu SY; Yang CP; Cheng TY; Chang CH; Liu TT; Lin CH; Kung HJ; Pan CC; Chang PC
Cancer Lett; 2018 Oct; 433():43-52. PubMed ID: 29944905
[TBL] [Abstract][Full Text] [Related]
19. Castration-Induced Downregulation of SPARC in Stromal Cells Drives Neuroendocrine Differentiation of Prostate Cancer.
Enriquez C; Cancila V; Ferri R; Sulsenti R; Fischetti I; Milani M; Ostano P; Gregnanin I; Mello-Grand M; Berrino E; Bregni M; Renne G; Tripodo C; Colombo MP; Jachetti E
Cancer Res; 2021 Aug; 81(16):4257-4274. PubMed ID: 34185677
[TBL] [Abstract][Full Text] [Related]
20. The prognostic significance of loss of the androgen receptor and neuroendocrine differentiation in prostate biopsy specimens among castration-resistant prostate cancer patients.
Komiya A; Yasuda K; Watanabe A; Fujiuchi Y; Tsuzuki T; Fuse H
Mol Clin Oncol; 2013 Mar; 1(2):257-262. PubMed ID: 24649157
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
